

Ismene L Petrakis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5695409/publications.pdf>

Version: 2024-02-01

127
papers

5,396
citations

101543

36
h-index

95266

68
g-index

128
all docs

128
docs citations

128
times ranked

5023
citing authors

#	ARTICLE	IF	CITATIONS
1	PTSD symptom heterogeneity and alcohol-related outcomes in U.S. military veterans: Indirect associations with coping strategies. <i>Journal of Anxiety Disorders</i> , 2022, 85, 102496.	3.2	8
2	Rationale, design and methods of VA-BRAVE: a randomized comparative effectiveness trial of two formulations of buprenorphine for treatment of opioid use disorder in veterans. <i>Addiction Science & Clinical Practice</i> , 2022, 17, 6.	2.6	3
3	Academic Medical Centers and the U.S. Department of Veterans Affairs: A 75-Year Partnership Influences Medical Education, Scientific Discovery, and Clinical Care. <i>Academic Medicine</i> , 2022, 97, 1110-1113.	1.6	4
4	Alcohol Craving and Psychiatric Disorders Among Current Drinkers. <i>American Journal on Addictions</i> , 2021, 30, 34-42.	1.4	4
5	Early discontinuation of pharmacotherapy in U.S. veterans diagnosed with PTSD and the role of psychotherapy. <i>Journal of Psychiatric Research</i> , 2021, 132, 167-173.	3.1	8
6	Sex Differences in Opioid Use Disorder Prevalence and Multimorbidity Nationally in the Veterans Health Administration. <i>Journal of Dual Diagnosis</i> , 2021, 17, 124-134.	1.2	11
7	Sex differences in progestogen- and androgen-derived neurosteroids in vulnerability to alcohol and stress-related disorders. <i>Neuropharmacology</i> , 2021, 187, 108499.	4.1	8
8	The Hidden Epidemic of Opioid Overdoses During the Coronavirus Disease 2019 Pandemic. <i>JAMA Psychiatry</i> , 2021, 78, 585.	11.0	24
9	COVID vaccine use in inpatient psychiatry units—The need is here and now. <i>General Hospital Psychiatry</i> , 2021, 71, 132-133.	2.4	1
10	Psychotherapy-supported MDMA treatment for PTSD. <i>Cell Reports Medicine</i> , 2021, 2, 100378.	6.5	6
11	Prevalence, risk and protective factors of alcohol use disorder during the COVID-19 pandemic in U.S. military veterans. <i>Drug and Alcohol Dependence</i> , 2021, 225, 108818.	3.2	17
12	Disentangling the association between PTSD symptom heterogeneity and alcohol use disorder: Results from the 2019–2020 National Health and Resilience in Veterans Study. <i>Journal of Psychiatric Research</i> , 2021, 142, 179-187.	3.1	8
13	Treatment outcomes in individuals diagnosed with comorbid opioid use disorder and Posttraumatic stress disorder: A review. <i>Addictive Behaviors</i> , 2021, 122, 107026.	3.0	6
14	Depression and/or PTSD Comorbidity Affects Response to Antidepressants in Those With Alcohol Use Disorder. <i>Frontiers in Psychiatry</i> , 2021, 12, 768318.	2.6	3
15	Trauma- and Stress-Induced Craving for Alcohol in Individuals Without PTSD. <i>Alcohol and Alcoholism</i> , 2020, 55, 37-43.	1.6	9
16	Donepezil and cognitive remediation therapy to augment treatment of alcohol use disorder related mild cognitive impairment (AUD-MCI): An open label pilot study with historical controls. <i>Substance Abuse</i> , 2020, 42, 1-5.	2.3	2
17	Zonisamide as an Adjunctive Treatment to Cognitive Processing Therapy for Veterans With Posttraumatic Stress Disorder and Comorbid Alcohol Use Disorder: A Pilot Study. <i>American Journal on Addictions</i> , 2020, 29, 515-524.	1.4	8
18	Randomized clinical trial of Cognitive Remediation Therapy with Work Therapy in the early phase of substance use disorder recovery for older Veterans: 12-Month follow-up. <i>Journal of Substance Abuse Treatment</i> , 2020, 112, 17-22.	2.8	3

#	ARTICLE	IF	CITATIONS
19	Systematic review and meta-analysis of the moderating effect of rs179971 in <i>OPRM1</i> , the mu-opioid receptor gene, on response to naltrexone treatment of alcohol use disorder. <i>Addiction</i> , 2020, 115, 1426-1437.	3.3	27
20	A Literature Review Examining Primary Outcomes of Medication Treatment Studies for Opioid Use Disorder: What Outcome Should Be Used to Measure Opioid Treatment Success?. <i>American Journal on Addictions</i> , 2020, 29, 249-267.	1.4	18
21	Thiopental Does Not Produce Hyperalgesia: A Laboratory Study Using Two Human Experimental Pain Models. <i>Pain Medicine</i> , 2020, 21, 2823-2829.	1.9	2
22	Is Pretreatment Blood Pressure a Marker of Prazosin Response in Posttraumatic Stress Disorder With Comorbid Alcohol Use Disorder?. <i>Biological Psychiatry</i> , 2019, 85, e11-e12.	1.3	3
23	How Important Is it for Psychiatrists to Be Competent in Motivational Interviewing?. <i>Academic Psychiatry</i> , 2019, 43, 528-531.	0.9	0
24	Rigorous Trial Design Is Essential to Understand the Role of Opioid Receptors in Ketamine's Antidepressant Effect—Reply. <i>JAMA Psychiatry</i> , 2019, 76, 658.	11.0	5
25	Targeting neuroinflammation with minocycline in heavy drinkers. <i>Psychopharmacology</i> , 2019, 236, 3013-3021.	3.1	20
26	Sex differences in stress-related alcohol use. <i>Neurobiology of Stress</i> , 2019, 10, 100149.	4.0	237
27	Alcohol Abstainer Status and Prazosin Treatment in Association with Changes in Posttraumatic Stress Disorder Symptoms in Veterans with Comorbid Alcohol Use Disorder and Posttraumatic Stress Disorder. <i>Alcoholism: Clinical and Experimental Research</i> , 2019, 43, 741-746.	2.4	11
28	Trauma treatment for veterans in buprenorphine maintenance treatment for opioid use disorder. <i>Addictive Behaviors</i> , 2019, 89, 29-34.	3.0	8
29	Trauma and Addiction—How to Treat Co-occurring PTSD and Substance Use Disorders. , 2019, , 189-196.		1
30	What Role Should Psychiatrists Have in Responding to the Opioid Epidemic?. <i>JAMA Psychiatry</i> , 2019, 76, 107.	11.0	14
31	Association of Combined Naltrexone and Ketamine With Depressive Symptoms in a Case series of Patients With Depression and Alcohol Use Disorder. <i>JAMA Psychiatry</i> , 2019, 76, 337.	11.0	104
32	A Pilot Randomized, Placebo-Controlled Trial of Glycine for Treatment of Schizophrenia and Alcohol Dependence. <i>Journal of Dual Diagnosis</i> , 2019, 15, 46-55.	1.2	9
33	Heart rate variability in alcohol use: A review. <i>Pharmacology Biochemistry and Behavior</i> , 2019, 176, 83-92.	2.9	49
34	Negative Affect Intensity and Hostility in Individuals With Alcohol Use Disorder With or Without Posttraumatic Stress Disorder. <i>Journal of Dual Diagnosis</i> , 2018, 14, 96-101.	1.2	0
35	Enhanced Striatal Dopamine Release to Expectation of Alcohol: A Potential Risk Factor for Alcohol Use Disorder. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2018, 3, 591-598.	1.5	16
36	Ghrelin is Related to Personality Differences in Reward Sensitivity and Impulsivity. <i>Alcohol and Alcoholism</i> , 2018, 53, 52-56.	1.6	35

#	ARTICLE	IF	CITATIONS
37	Effect of Varenicline Combined With Medical Management on Alcohol Use Disorder With Comorbid Cigarette Smoking. <i>JAMA Psychiatry</i> , 2018, 75, 129.	11.0	79
38	Description of a Comprehensive Addiction Rotation at a Psychiatry Residency Program. <i>Academic Psychiatry</i> , 2018, 42, 313-316.	0.9	2
39	Mecamylamine treatment for alcohol dependence: a randomized controlled trial. <i>Addiction</i> , 2018, 113, 6-14.	3.3	23
40	Tobacco use during a clinical trial of mecamylamine for alcohol dependence: Medication effects on smoking and associations with reductions in drinking. <i>Journal of Substance Abuse Treatment</i> , 2018, 94, 91-96.	2.8	6
41	Pharmacological and Psychological Treatments for Comorbid Alcohol Use Disorder and Depressive Disorder: a Review. <i>Current Addiction Reports</i> , 2018, 5, 312-322.	3.4	6
42	Pharmacotherapy for Co-Occurring Alcohol Use Disorder and Post-Traumatic Stress Disorder: Targeting the Opioidergic, Noradrenergic, Serotonergic, and GABAergic/Glutamatergic Systems. <i>Alcohol Research: Current Reviews</i> , 2018, 39, 193-205.	3.6	3
43	Treatment of alcohol use disorder and co-occurring PTSD. <i>American Journal of Drug and Alcohol Abuse</i> , 2017, 43, 391-401.	2.1	23
44	Posttraumatic Stress Disorder and Alcohol Use Disorder: A Critical Review of Pharmacologic Treatments. <i>Alcoholism: Clinical and Experimental Research</i> , 2017, 41, 226-237.	2.4	61
45	A Comparison of Sexual Side Effects of Antidepressants With and Without Naltrexone. <i>Journal of Dual Diagnosis</i> , 2017, 13, 230-235.	1.2	2
46	The Importance of Identifying Characteristics Underlying the Vulnerability to Develop Alcohol Use Disorder. <i>American Journal of Psychiatry</i> , 2017, 174, 1034-1035.	7.2	3
47	Three-year retention in buprenorphine treatment for opioid use disorder nationally in the Veterans Health Administration. <i>American Journal on Addictions</i> , 2017, 26, 572-580.	1.4	67
48	Partnering with Psychiatry to Close the Education Gap: An Approach to the Addiction Epidemic. <i>Journal of General Internal Medicine</i> , 2017, 32, 1387-1389.	2.6	17
49	<i>GRIK1</i> and <i>GABRA2</i> Variants Have Distinct Effects on the Dose-Related Subjective Response to Intravenous Alcohol in Healthy Social Drinkers. <i>Alcoholism: Clinical and Experimental Research</i> , 2017, 41, 2025-2032.	2.4	9
50	Ghrelin is Suppressed by Intravenous Alcohol and is Related to Stimulant and Sedative Effects of Alcohol. <i>Alcohol and Alcoholism</i> , 2017, 52, 431-438.	1.6	35
51	NMDA Glutamate Receptor Antagonism and the Heritable Risk for Alcoholism: New Insights from a Study of Nitrous Oxide. <i>International Journal of Neuropsychopharmacology</i> , 2017, 20, 351-353.	2.1	2
52	Naltrexone and Disulfiram Treatment Response in Veterans With Alcohol Dependence and Co-Occurring Problem-Gambling Features. <i>Journal of Clinical Psychiatry</i> , 2017, 78, e1299-e1306.	2.2	62
53	Effect of Intravenous Ethanol on Capsaicin-Induced Hyperalgesia in Human Subjects. <i>Alcoholism: Clinical and Experimental Research</i> , 2016, 40, 1425-1429.	2.4	20
54	Prazosin for Veterans with Posttraumatic Stress Disorder and Comorbid Alcohol Dependence: A Clinical Trial. <i>Alcoholism: Clinical and Experimental Research</i> , 2016, 40, 178-186.	2.4	94

#	ARTICLE	IF	CITATIONS
55	Dyslipidemia associated with heavy alcohol use. <i>American Journal on Addictions</i> , 2016, 25, 188-190.	1.4	11
56	An Innovative Use of Case Conference to Teach Future Educators in Addiction Psychiatry. <i>Academic Psychiatry</i> , 2016, 40, 494-497.	0.9	4
57	Familial Alcoholism Risk and the Ratio of Stimulant to Sedative Effects of Ketamine. <i>Biological Psychiatry</i> , 2016, 79, e69-e70.	1.3	7
58	Trauma- and Stress-Induced Response in Veterans with Alcohol Dependence and Comorbid Post-Traumatic Stress Disorder. <i>Alcoholism: Clinical and Experimental Research</i> , 2016, 40, 1752-1760.	2.4	22
59	Alcohol Use Disorders and Comorbid Post-Traumatic Stress Disorder in US Military Veterans: Etiology and Current Treatment Approaches. , 2016, , 627-642.		1
60	Integrating acquired preparedness and dual process models of risk for heavy drinking and related problems.. <i>Psychology of Addictive Behaviors</i> , 2015, 29, 864-874.	2.1	21
61	Preliminary analysis of positive and negative syndrome scale in ketamine-associated psychosis in comparison with schizophrenia. <i>Journal of Psychiatric Research</i> , 2015, 61, 64-72.	3.1	50
62	Correlates of major depressive disorder with and without comorbid alcohol use disorder nationally in the veterans health administration. <i>American Journal on Addictions</i> , 2015, 24, 419-426.	1.4	17
63	Alcohol Use Disorders and Comorbid Posttraumatic Stress Disorder in US Military Veterans: Etiology and Current Treatment Approaches. , 2015, , 1-13.		0
64	How to Best Treat Patients With Schizophrenia and Co-Occurring Alcohol Use Disorder. <i>Journal of Clinical Psychiatry</i> , 2015, 76, e1338-e1339.	2.2	1
65	PTSD and comorbid AUD: a review of pharmacological and alternative treatment options. <i>Substance Abuse and Rehabilitation</i> , 2014, 5, 25.	4.8	40
66	Pharmacogenetics of naltrexone and disulfiram in alcohol dependent, dually diagnosed veterans. <i>American Journal on Addictions</i> , 2014, 23, 288-293.	1.4	34
67	A Commentary on Topiramate Treatment of Alcohol Use Disorder in Veterans with PTSD: A Randomized Controlled Pilot Trial. <i>Alcoholism: Clinical and Experimental Research</i> , 2014, 38, 2167-2168.	2.4	0
68	Relationships between impulsivity and subjective response in an IV ethanol paradigm. <i>Psychopharmacology</i> , 2014, 231, 2867-2876.	3.1	29
69	Quality of life in veterans with alcohol dependence and co-occurring mental illness. <i>Addictive Behaviors</i> , 2014, 39, 386-391.	3.0	7
70	Characteristics and drinking patterns of veterans with alcohol dependence with and without post-traumatic stress disorder. <i>Addictive Behaviors</i> , 2014, 39, 374-378.	3.0	20
71	Pharmacological treatment of comorbid PTSD and substance use disorder: Recent progress. <i>Addictive Behaviors</i> , 2014, 39, 428-433.	3.0	52
72	Disulfiram for Alcohol and Other Drug Use. , 2013, , 367-374.		0

#	ARTICLE	IF	CITATIONS
73	Effects of Family History of Alcohol Dependence on the Subjective Response to Alcohol Using the Intravenous Alcohol Clamp. <i>Alcoholism: Clinical and Experimental Research</i> , 2013, 37, 2011-2018.	2.4	28
74	Mecamylamine for Treatment of People With Dual Diagnoses of Depression and Alcohol Dependence. <i>Journal of Dual Diagnosis</i> , 2013, 9, 301-310.	1.2	3
75	Noradrenergic vs Serotonergic Antidepressant with or without Naltrexone for Veterans with PTSD and Comorbid Alcohol Dependence. <i>Neuropsychopharmacology</i> , 2012, 37, 996-1004.	5.4	104
76	Intravenous Ethanol Infusion Decreases Human Cortical $\hat{1}^3$ -Aminobutyric Acid and N-Acetylaspartate as Measured with Proton Magnetic Resonance Spectroscopy at 4 Tesla. <i>Biological Psychiatry</i> , 2012, 71, 239-246.	1.3	74
77	Acute Postoperative Pain. <i>Journal of Anesthesia & Clinical Research</i> , 2012, s7, .	0.1	2
78	Substance use and schizophrenia: Adverse correlates in the CATIE study sample. <i>Schizophrenia Research</i> , 2011, 132, 177-182.	2.0	56
79	Substance Use Comorbidity among Veterans with Posttraumatic Stress Disorder and Other Psychiatric Illness. <i>American Journal on Addictions</i> , 2011, 20, 185-189.	1.4	118
80	Case report on the use of cognitive processing therapyâ€œcognitive, enhanced to address heavy alcohol use. <i>Journal of Traumatic Stress</i> , 2011, 24, 474-478.	1.8	19
81	Treatment With Acamprosate in Patients With Schizophrenia Spectrum Disorders and Comorbid Alcohol Dependence. <i>Journal of Dual Diagnosis</i> , 2011, 7, 64-73.	1.2	17
82	Dual Diagnosis in an Aging Population: Prevalence of Psychiatric Disorders, Comorbid Substance Abuse, and Mental Health Service Utilization in the Department of Veterans Affairs. <i>Journal of Dual Diagnosis</i> , 2011, 7, 4-13.	1.2	23
83	Characterization of the Interactive Effects of Glycine and D-Cycloserine in Men: Further Evidence for Enhanced NMDA Receptor Function Associated with Human Alcohol Dependence. <i>Neuropsychopharmacology</i> , 2011, 36, 701-710.	5.4	32
84	Novel Pharmacological Approaches to Drug Abuse Treatment. <i>Current Topics in Behavioral Neurosciences</i> , 2010, 3, 343-386.	1.7	14
85	Epidemiology and Management of Alcohol Dependence in Individuals with Post-Traumatic Stress Disorder. <i>CNS Drugs</i> , 2010, 24, 997-1007.	5.9	84
86	Varenicline Reduces Alcohol Self-Administration in Heavy-Drinking Smokers. <i>Biological Psychiatry</i> , 2009, 66, 185-190.	1.3	275
87	Modulation of the cortical processing of novel and target stimuli by drugs affecting glutamate and GABA neurotransmission. <i>International Journal of Neuropsychopharmacology</i> , 2009, 12, 357.	2.1	65
88	Pharmacotherapeutic Effects of Opioid Antagonists in Alcohol-Abusing Patients with Schizophrenia. , 2009, , 473-483.		1
89	Absence of Significant Interactive Effects of Highâ€Dose <sc>d</sc>â€Cycloserine and Ethanol in Healthy Human Subjects: Preliminary Insights Into Ethanol Actions at the Glycine_B Site of NMDA Glutamate Receptors. <i>Alcoholism: Clinical and Experimental Research</i> , 2008, 32, 36-42.	2.4	10
90	Ethanol and Pain Sensitivity: Effects in Healthy Subjects Using an Acute Pain Paradigm. <i>Alcoholism: Clinical and Experimental Research</i> , 2008, 32, 952-958.	2.4	50

#	ARTICLE	IF	CITATIONS
91	Naltrexone and Disulfiram in Patients With Alcohol Dependence and Current Depression. <i>Journal of Clinical Psychopharmacology</i> , 2007, 27, 160-165.	1.4	56
92	The Impact of Personality Disorders on Alcohol Use Outcomes in a Pharmacotherapy Trial for Alcohol Dependence and Comorbid Axis I Disorders. <i>American Journal on Addictions</i> , 2007, 16, 443-449.	1.4	29
93	Psychiatric safety of ketamine in psychopharmacology research. <i>Psychopharmacology</i> , 2007, 192, 253-260.	3.1	104
94	Effects of Naltrexone on Cognition in a Treatment Study of Patients with Schizophrenia and Comorbid Alcohol Dependence. <i>Journal of Dual Diagnosis</i> , 2006, 2, 53-69.	1.2	5
95	Cortical Gamma-Aminobutyric Acid Levels and the Recovery from Ethanol Dependence: Preliminary Evidence of Modification by Cigarette Smoking. <i>Biological Psychiatry</i> , 2006, 59, 85-93.	1.3	71
96	Naltrexone and Disulfiram in Patients with Alcohol Dependence and Comorbid Post-Traumatic Stress Disorder. <i>Biological Psychiatry</i> , 2006, 60, 777-783.	1.3	125
97	A Rational Approach to the Pharmacotherapy of Alcohol Dependence. <i>Journal of Clinical Psychopharmacology</i> , 2006, 26, S3-S12.	1.4	23
98	Atypical Antipsychotic Medication and Substance Use-Related Outcomes in the Treatment of Schizophrenia. <i>American Journal on Addictions</i> , 2006, 15, 44-49.	1.4	28
99	The vulnerability to alcohol and substance abuse in individuals diagnosed with schizophrenia. <i>Neurotoxicity Research</i> , 2006, 10, 235-252.	2.7	65
100	$\hat{\beta}$ -Aminobutyric Acid Type A Receptors and Alcoholism. <i>Archives of General Psychiatry</i> , 2006, 63, 957.	12.3	181
101	Cortical $\hat{\beta}$ -Aminobutyric Acid Type A Benzodiazepine Receptors in Recovery From Alcohol Dependence. <i>Archives of General Psychiatry</i> , 2005, 62, 877.	12.3	45
102	Mazindol Augmentation of Antipsychotic Treatment for Schizophrenic Patients with Comorbid Cocaine Abuse or Dependence. <i>Journal of Dual Diagnosis</i> , 2005, 1, 37-47.	1.2	5
103	Psychotic Spectrum Disorders and Alcohol Abuse: A Review of Pharmacotherapeutic Strategies and a Report on the Effectiveness of Naltrexone and Disulfiram. <i>Schizophrenia Bulletin</i> , 2005, 32, 644-654.	4.3	69
104	Pharmacotherapy of Alcohol Use Disorders. <i>Substance Use and Misuse</i> , 2005, 40, 2001-2020.	1.4	20
105	Naltrexone and Disulfiram in Patients with Alcohol Dependence and Comorbid Psychiatric Disorders. <i>Biological Psychiatry</i> , 2005, 57, 1128-1137.	1.3	183
106	Naltrexone augmentation of neuroleptic treatment in alcohol abusing patients with schizophrenia. <i>Psychopharmacology</i> , 2004, 172, 291-297.	3.1	109
107	Altered NMDA Glutamate Receptor Antagonist Response in Individuals With a Family Vulnerability to Alcoholism. <i>American Journal of Psychiatry</i> , 2004, 161, 1776-1782.	7.2	128
108	NMDA Receptor Antagonism and the Ethanol Intoxication Signal. <i>Annals of the New York Academy of Sciences</i> , 2003, 1003, 176-184.	3.8	130

#	ARTICLE	IF	CITATIONS
109	N-methyl-d-aspartate glutamate receptors and alcoholism: reward, dependence, treatment, and vulnerability. , 2003, 99, 79-94.		290
110	Use of Naltrexone in the Treatment of Alcoholism Nationally in the Department of Veterans Affairs. Alcoholism: Clinical and Experimental Research, 2003, 27, 1780-1784.	2.4	28
111	Altered NMDA Glutamate Receptor Antagonist Response in Recovering Ethanol-Dependent Patients. Neuropsychopharmacology, 2003, 28, 2020-2028.	5.4	82
112	The Use of Antidepressants in Alcohol-Dependent Veterans. Journal of Clinical Psychiatry, 2003, 64, 865-870.	2.2	9
113	The Effect of Tryptophan Depletion on Alcohol Self-Administration in Non-Treatment-Seeking Alcoholic Individuals. Alcoholism: Clinical and Experimental Research, 2002, 26, 969-975.	2.4	22
114	The effect of tryptophan depletion on alcohol self-administration in non-treatment-seeking alcoholic individuals. Alcoholism: Clinical and Experimental Research, 2002, 26, 969-75.	2.4	7
115	Effect of Tryptophan Depletion on Alcohol Cue-Induced Craving in Abstinent Alcoholic Patients. Alcoholism: Clinical and Experimental Research, 2001, 25, 1151-1155.	2.4	25
116	Effect of Tryptophan Depletion on Alcohol Cue-Induced Craving in Abstinent Alcoholic Patients. Alcoholism: Clinical and Experimental Research, 2001, 25, 1151-1155.	2.4	2
117	Similarities in the Disturbances in Cortical Information Processing in Alcoholism and Aging: A Pilot Evoked Potential Study. International Psychogeriatrics, 2000, 12, 513-525.	1.0	28
118	Sex Differences in Self-Reported and Physiological Response to Oral Cocaine and Placebo in Humans. American Journal of Drug and Alcohol Abuse, 2000, 26, 643-657.	2.1	16
119	Disulfiram treatment for cocaine dependence in methadone-maintained opioid addicts. Addiction, 2000, 95, 219-228.	3.3	183
120	CSF Monoamine Metabolite and Beta Endorphin Levels in Recently Detoxified Alcoholics and Healthy Controls: Prediction of Alcohol Cue-Induced Craving?. Alcoholism: Clinical and Experimental Research, 1999, 23, 1336-1341.	2.4	19
121	Toward a rational pharmacotherapy of comorbid substance abuse in schizophrenic patients. Schizophrenia Research, 1999, 35, S35-S49.	2.0	84
122	Preliminary Evidence of Low Cortical GABA Levels in Localized ¹ H-MR Spectra of Alcohol-Dependent and Hepatic Encephalopathy Patients. American Journal of Psychiatry, 1999, 156, 952-954.	7.2	146
123	Alterations of Benzodiazepine Receptors in Type II Alcoholic Subjects Measured With SPECT and [¹²³ I]Iomazenil. American Journal of Psychiatry, 1998, 155, 1550-1555.	7.2	395
124	Dose-Related Ethanol-like Effects of the NMDA Antagonist, Ketamine, in Recently Detoxified Alcoholics. Archives of General Psychiatry, 1998, 55, 354-60.	12.3	137
125	Naltrexone Augmentation of Neuroleptics in Schizophrenia. Journal of Clinical Psychopharmacology, 1998, 18, 248-251.	1.4	36
126	AMPT Effects on Cue-Induced Craving for Cocaine. American Journal on Addictions, 1996, 5, 313-320.	1.4	1

#	ARTICLE	IF	CITATIONS
127	Fluoxetine Treatment for Dually Diagnosed Methadone Maintained Opioid Addicts:. Journal of Addictive Diseases, 1995, 13, 25-32.	1.3	12